Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.56Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -25.32%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trials, financial strengthening, and potential revenue growth for ZYNLONTA. However, it also acknowledged challenges such as competition in the DLBCL market and flat revenue growth. Despite these challenges, the company remains optimistic about its future prospects.Company Guidance
During ADC Therapeutics' fourth-quarter fiscal year 2024 earnings call, the company provided comprehensive guidance on its financial performance and strategic advancements. CEO Ameet Mallik highlighted key milestones, including achieving commercial brand profitability with ZYNLONTA, reporting sales of $69.3 million, and completing enrollment for the pivotal Phase 3 LOTIS-5 trial, aiming to expand ZYNLONTA's use in earlier lines of DLBCL therapy. The company also achieved a double-digit reduction in operating expenses for the second consecutive year and strengthened its balance sheet through equity financing, ensuring a cash runway into the second half of 2026. CFO Pepe Carmona reported a GAAP net loss of $30.7 million for the quarter, a significant improvement from the previous year's $85 million, driven by reduced operating expenses and lower income tax expenses. ADC Therapeutics anticipates reaching peak revenues of $600 million to $1 billion in the U.S., contingent on regulatory approvals and compendia listings.ZYNLONTA Commercial Brand Profitability
ZYNLONTA reached commercial brand profitability, maintaining its position in the competitive third-line-plus DLBCL space with sales of $69.3 million, consistent with the previous year.
Advancements in Clinical Trials
Completion of enrollment in pivotal Phase 3 LOTIS-5 trial and initial efficacy and safety update on Phase 1b LOTIS-7 trial. Initial data showed promising response rates.
Reduction in Operating Expenses
Achieved a double-digit reduction in operating expenses for the second consecutive year, with a 13% year-over-year decrease on a non-GAAP basis.
Strengthened Financial Position
Strengthened balance sheet through equity financing, providing a cash runway into the second half of 2026, with $251 million in cash and equivalents.
Promising Data Presentation
Promising Phase 2 data presented for indolent lymphomas at ASH, with strong response rates in high-risk relapsed/refractory FL and MZL patients.
Potential Revenue Growth
Potential peak revenue of $600 million to $1 billion in the US for ZYNLONTA, assuming regulatory approval and compendia listing.
---
ADCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.58 | $1.52 | -3.80% |
| Nov 07, 2024 | $3.20 | $2.93 | -8.44% |
| Aug 06, 2024 | $2.87 | $2.92 | +1.74% |
| May 06, 2024 | $4.90 | $4.45 | -9.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ADC Therapeutics Ltd (ADCT) report earnings?
ADC Therapeutics Ltd (ADCT) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is ADC Therapeutics Ltd (ADCT) earnings time?
ADC Therapeutics Ltd (ADCT) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADCT EPS forecast?
ADCT EPS forecast for the fiscal quarter 2025 (Q1) is -0.4.
---